BON Bon Natural Life Limited
Listings ·
Bon Natural Life's unaudited interim statements for the six months to March 31, 2025, filed in a Form 6-K on September 29, 2025, reflect a 1-for-25 share consolidation and net proceeds of $10,543,805 from a public offering of Class A ordinary shares. Cash rose from $80,466 to $8,894,053 over the period.
Bon Natural Life says Nasdaq has closed its bid price matter after the Hearings Panel decision, but the company stays under a one-year Discretionary Panel Monitor. The Nasdaq confirmation came on July 29, 2025, and the company reported it in a Form 6-K dated August 4, 2025.
Bon Natural Life's board approved a share repurchase of up to $1.0 million of its Class A ordinary shares, to be bought in the open market by TradeUp Securities as exclusive agent. The company says it is not obliged to buy any particular number of shares and may suspend the program at any time.
| Line | FY ended Sep 30, 2025 | FY ended Sep 30, 2024 |
|---|---|---|
| Revenue | $18.7 million | $23.8 million |
| Research and development | $754,193 | $1.6 million |
| Net income (loss) | -$2.0 million | $398,172 |
| Cash from operations | $141,115 | -$7.7 million |
| Cash and equivalents | $6.3 million | $80,466 |
Our latest story on this, dated Sep 29, 2025: "Bon Natural Life's interim results reflect 1-for-25 share consolidation and offering". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 3, 2025: "Bon Natural Life announces share buyback of up to $1.0 million". The story links the filing or release it is based on. Read the story.
Bon Natural Life Limited trades under the ticker BON on NASDAQ.
Bon Natural Life Limited is listed on NASDAQ.
The SEC Central Index Key (CIK) for Bon Natural Life Limited is 1816815. Its filings are on SEC EDGAR.
3,970,558 shares as of 2024-09-30, per the cover page of its 20-F filed 2025-01-28.
Our directory records Bon Natural Life Limited under China.
Our directory classifies Bon Natural Life Limited as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Bon Natural Life Limited is KYG144922047.
aibio.space lists Bon Natural Life Limited among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as E9.
$18.7 million for the fiscal year ended Sep 30, 2025, as reported to the SEC.
Bon Natural Life Limited reported a net loss of $2.0 million for the fiscal year ended Sep 30, 2025, and generated $141,115 of cash from operations, per its annual report to the SEC.
$754,193 in the fiscal year ended Sep 30, 2025, per its annual report.
$6.3 million in cash at Sep 30, 2025, per its 20-F.
Reported a financing. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Announced a share repurchase program. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Filed a registration statement for a share offering. SEC Form F-1. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio